Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas

Annals of Thoracic Surgery

Volumn 77, Issue 6, 2004, Pages 1883-1890

  Ab' Saber, Alexandre M ^a   Massoni Neto, Ledo Mazzei ^a   Bianchi, Cristina P ^a   Ctenas, Bruno B ^a   Parra, Edwin R ^a   Eher, Esmeralda M ^a   Pereira, João Carlos ^a   Takagaki, Teresa ^a   Yamaguchi, Nise H ^a   Capelozzi, Vera L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

10

Indexed keywords

TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DEATH; CLINICAL FEATURE; CONTROLLED STUDY; DENSITY; EXCISION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG CARCINOMA; MEDICAL EXAMINATION; MEDICAL INFORMATION; MICROVASCULATURE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PULMONARY LARGE CELL CARCINOMA; QUANTITATIVE ANALYSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2542541248     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2003.11.047     Document Type: Article

References (27)

1. Wick M.R., Berg L.C., Usak M., Hertz M.I. Large cell carcinoma of the lung with neuroendocrine differentiation. A comparison with large cell "undifferentiated" pulmonary tumors. Am J Clin Pathol. 97:1992;796-805
2. Delmonte Capelozzi V., Alberti O., Saldiva P.H.N. Large cell carcinoma of the lung ultrastructural and immunohistochemical features. Chest. 90:1986;524-526
3. Travis W.D., Linnoila R.I., Tsokos M.G., et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 15:1991;529-553
4. Dressler C.M., Ritter J.H., Patterson G.A., Ross E., Bailey M.S., Wick M.R. Clinicopathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 63:1997;180-185
5. Garcia-Yuste M., Matilla J.M., Alvarez-Gago T., Duque J.L., Cerezal L.J., Ramos G. Prognostic factors in neuroendocrine lung tumors a Spanish multicentre study. Ann Thorac Surg. 70:2000;258-263
6. Travis W.D., Corrin B., Shimosato Y., Brambilla E. The histological typing of lung and pleural tumors. WHO/IASLC classification of lung and pleural tumours. 3rd ed:1999;Springer Verlag, Berlin
7. Iyoda A., Hiroshima K., Toyozaki T., Haga Y., Fujisawa T., Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 91:2001;1992-2000
8. Iyoda A., Hiroshima K., Masayuki B., Saitoh Y., Ohwada H., Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg. 73:2002;1049-1054
9. Zacharias J., Nicholson A.G., Ladas G.P., Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg. 75:2003;348-352
10. Przygodzki R.M., Finkelstein S.D., Langer J.C., et al. Analysis of p53, K-ras-2, and C-ralf-1 in pulmonary neuroendocrine tumors correlation with histological subtype and clinical outcome. Am J Pathol. 148:1996;1531-1541
11. Battlehner C.N., Saldiva P.H.N., Carvalho C.R.R., et al. Nuclear/cytoplasmic ratio correlates strongly with survival in non-disseminated neuroendocrine carcinoma of the lung. Histopathology. 22:1993;31-34
12. Caporrino C., Saldiva P.H.N., Farhat C.A., Takagaki T.Y., Younes R.Y., Capelozzi V.L. Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung. Histopathology. 31:1997;420-429
13. Carvalho P.E.O., Antonângelo L., Bernardi F.D.C., Leão L.E.V., Rodrigues O.R.R., Capelozzi V.L. Useful prognostic panel marker to express the biological tumor status in resected lung adenocarcinomas. Jpn J Clin Oncol. 30:2000;478-486
14. Capelozzi V., Battlehner C.N., Montes G.S., Saldiva P.H.N. Volume fraction of dense-core granules correlates well with survival in disseminated (stage IV) neuroendocrine carcinoma of the lung. Pathol Res Pract. 189:1993;1145-1148
15. Demarchi L.M., Reis M.M., Palomino S.A., et al. Prognostic values of stromal density and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol. 13:2000;511-520
16. waf1cip1, and transforming growth factor β1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res. 4:1998;1499-1506
17. Khan Q.A., Dipple A., Anderson L.M. Protease inhibitor-induced stabilization of p21(waf1/cip1) and cell-cycle arrest in chemical carcinogen-exposed mammary and lung cells. Mol Carcinog. 33:2002;1-8
18. DiGiuseppe J.Á., Redston M.S., Veo C.J., Kern S.E., Hruban R.H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 147:1995;884-888
19. Marchetti A., Doglioni C., Barbareschi M., et al. p21 RNA and protein expression in non-small cell lung carcinomas evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 12:1996;1319-1324
20. Barbareschi M., Caffo O., Doglioni V.C., et al. P21 immunohistochemical expression in breast carcinoma correlations with clinicopathologic data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 74:1996;208-215
21. Fontanini G., Lucchi M., Vignati S., et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma a prospective study. J Natl Cancer Inst. 89:1997;881-886
22. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors implications for antiangiogenic tumor therapies. Cancer Res. 60:2000;1388-1393
23. Brem S., Cotran R., Folkman J. Tumor angiogenesis a quantitative method for histologic grading. J Natl Cancer Inst. 48:1992;347-356
24. Slodkowska J., Sikora J., Androsiuk W., Rudzinski P., Radomyski A. Lung carcinoids. Tumor angiogenesis in relation to clinicopathologic characteristics. Anal Quant Cytol Histol. 21:1999;267-272
25. Garzetti G.G., Ciavattini A., Lucarini G., et al. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer. 85:1999;2219-2225
26. Hilliard J.E. Measurements of volume in volume. DeHoff R.T., Rhines F.N. Quantitative microscopy. 1968;48-49 McGraw-Hill, New York
27. Gundersen H.J., Bendtsen T.F., Korbo L., et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 96:1988;379-394